GLYC - GLYCOMIMETICS INC

QQQ $ 479.30 $ 2.47 (0.52 %)

DIA $ 386.46 $ -0.42 (-0.11 %)

SPY $ 542.65 $ 0.33 (0.06 %)

TLT $ 94.67 $ 0.79 (0.84 %)

GLD $ 215.76 $ 2.76 (1.3 %)

Previous Close

$ 0.263

Open

$ 0.27

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 0.26 - $ 0.27

52 Week Range

$ 0.25 - $ 3.53

Volume

552,371

Average Volume

Market Cap

16.95M

Beta (5Y Monthly)

$ 1.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	03-27-2024	12-31-2023	10-K
3	11-03-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	03-29-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	04-28-2022	03-31-2022	10-Q
10	03-03-2022	12-31-2021	10-K
11	11-02-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-03-2021	03-31-2021	10-Q
14	03-02-2021	12-31-2020	10-K
15	11-06-2020	09-30-2020	10-Q
16	07-31-2020	06-30-2020	10-Q
17	05-01-2020	03-31-2020	10-Q
18	02-28-2020	12-31-2019	10-K
19	11-07-2019	09-30-2019	10-Q
20	08-01-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	03-06-2019	12-31-2018	10-K
23	11-02-2018	09-30-2018	10-Q
24	08-09-2018	06-30-2018	10-Q
25	05-03-2018	03-31-2018	10-Q
26	03-06-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-08-2017	03-31-2017	10-Q
30	03-01-2017	12-31-2016	10-K
31	11-04-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-04-2016	03-31-2016	10-Q
34	02-29-2016	12-31-2015	10-K
35	11-12-2015	09-30-2015	10-Q
36	08-06-2015	06-30-2015	10-Q
37	05-05-2015	03-31-2015	10-Q
38	03-16-2015	12-31-2014	10-K
39	10-31-2014	09-30-2014	10-Q
40	07-31-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Neutral on ...
06/04/2024 20:12:22

HC Wainwright & Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:GLYC) with a Neutral.

$glycomimetics-shares-detailed-results-from-its-pivotal-phase-3-study-of-uproleselan-in-relapsedrefractory-acute-myeloid-leukemia$

GlycoMimetics Shares Detailed Results From...
06/04/2024 11:09:16

Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinica...

$glycomimetics-to-host-leader-event-to-review-results-from-pivotal-phase-3-study-of-uproleselan-in-relapsedrefractory-acute-myeloid-leukemia-on-june-4-2024$

GlycoMimetics To Host Leader Event To Revi...
05/29/2024 20:03:25

GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based the...